Literature DB >> 29116368

N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges.

Twanette Swanepoel1, Marisa Möller1, Brian Herbert Harvey2,3.   

Abstract

RATIONALE: Schizophrenia is associated with prenatal inflammation and/or postnatal stressors such as drug abuse, resulting in immune-redox dysfunction. Antioxidants may offer therapeutic benefits.
OBJECTIVES: The objective of this study is to investigate N-acetyl cysteine (NAC) as a therapeutic antioxidant to reverse schizophrenia-like bio-behavioural changes in rats exposed to maternal immune activation (MIA), adolescent methamphetamine (MA) or a combination thereof.
METHODS: Sprague-Dawley offspring prenatally exposed to saline/lipopolysaccharide (LPS) received saline or MA (0.2-6 mg kg-1 twice daily × 16 days) during adolescence and divided into LPS, MA and LPS + MA groups. Vehicle/NAC (150 mg kg-1 × 14 days) was administered following MA/saline exposure on postnatal day 51-64. Social interaction, novel object recognition and prepulse inhibition (PPI) of startle, as well as regional brain monoamines, lipid peroxidation, plasma reactive oxygen species (ROS) and pro- and anti-inflammatory cytokines (TNF-α; IL-10), were assessed.
RESULTS: NAC reversed LPS, MA and LPS + MA-induced anxiety-like social withdrawal behaviours, as well as MA and LPS + MA-induced deficits in recognition memory. PPI deficits were evident in MA, LPS and LPS + MA models, with NAC reversing that following LPS + MA. NAC reversed LPS, MA and LPS + MA-induced frontal cortical dopamine (DA) and noradrenaline (NA) elevations, LPS and LPS + MA-induced frontal cortical 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin (5-HT) and striatal NA deficits as well as LPS + MA-induced frontal cortical 5-HT turnover. Decreased IL-10 in the LPS, MA and LPS + MA animals, and increased TNF-α in the LPS and MA animals, was reversed with NAC. NAC also reversed elevated lipid peroxidation and ROS in the LPS and LPS + MA animals.
CONCLUSIONS: Prenatal LPS, LPS + postnatal MA challenge during adolescence, and to a lesser extent MA alone, promotes schizophrenia-like bio-behavioural changes later in life that are reversed by NAC, emphasizing therapeutic potential for schizophrenia and MA-associated psychosis. The nature and timing of the dual-hit are critical.

Entities:  

Keywords:  Dual-hit; Methamphetamine; N-acetyl cysteine; Neurodevelopmental model; Prenatal infection; Psychosis

Mesh:

Substances:

Year:  2017        PMID: 29116368     DOI: 10.1007/s00213-017-4776-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  101 in total

Review 1.  Effects of prenatal infection on brain development and behavior: a review of findings from animal models.

Authors:  Patricia Boksa
Journal:  Brain Behav Immun       Date:  2010-03-15       Impact factor: 7.217

2.  Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats.

Authors:  Michèle Crumeyrolle-Arias; Mathilde Jaglin; Aurélia Bruneau; Sylvie Vancassel; Ana Cardona; Valérie Daugé; Laurent Naudon; Sylvie Rabot
Journal:  Psychoneuroendocrinology       Date:  2014-01-31       Impact factor: 4.905

3.  A meta-analysis of oxidative stress markers in schizophrenia.

Authors:  Ming Zhang; ZhongMing Zhao; Lin He; ChunLing Wan
Journal:  Sci China Life Sci       Date:  2010-02-12       Impact factor: 6.038

Review 4.  Developmental neuroinflammation and schizophrenia.

Authors:  Urs Meyer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-11-15       Impact factor: 5.067

5.  A "double hit" murine model for schizophrenia shows alterations in the structure and neurochemistry of the medial prefrontal cortex and the hippocampus.

Authors:  Javier Gilabert-Juan; Maria Belles; Ana Rosa Saez; Hector Carceller; Sara Zamarbide-Fores; Maria Dolores Moltó; Juan Nacher
Journal:  Neurobiol Dis       Date:  2013-07-26       Impact factor: 5.996

6.  The startle reflex in schizophrenia: habituation and personality correlates.

Authors:  Sare J Akdag; Paul G Nestor; Brian F O'Donnell; Margaret A Niznikiewicz; Martha E Shenton; Robert W McCarley
Journal:  Schizophr Res       Date:  2003-11-15       Impact factor: 4.939

Review 7.  A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.

Authors:  Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2016-04-09       Impact factor: 8.989

Review 8.  The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.

Authors:  Oliver D Howes; Robert McCutcheon; Michael J Owen; Robin M Murray
Journal:  Biol Psychiatry       Date:  2016-08-06       Impact factor: 13.382

Review 9.  The novel object recognition memory: neurobiology, test procedure, and its modifications.

Authors:  M Antunes; G Biala
Journal:  Cogn Process       Date:  2011-12-09

Review 10.  Fetal programming of schizophrenia: select mechanisms.

Authors:  Monojit Debnath; Ganesan Venkatasubramanian; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2014-12-10       Impact factor: 8.989

View more
  11 in total

Review 1.  AMPed-up adolescents: The role of age in the abuse of amphetamines and its consequences on cognition and prefrontal cortex development.

Authors:  Sara R Westbrook; Lauren K Carrica; Asia Banks; Joshua M Gulley
Journal:  Pharmacol Biochem Behav       Date:  2020-08-20       Impact factor: 3.533

Review 2.  Potential Roles of Redox Dysregulation in the Development of Schizophrenia.

Authors:  Diana O Perkins; Clark D Jeffries; Kim Q Do
Journal:  Biol Psychiatry       Date:  2020-04-02       Impact factor: 13.382

3.  Immune Activation in Pregnant Rats Affects Brain Glucose Consumption, Anxiety-like Behaviour and Recognition Memory in their Male Offspring.

Authors:  Cyprien G J Guerrin; Alexandre Shoji; Janine Doorduin; Erik F J de Vries
Journal:  Mol Imaging Biol       Date:  2022-04-05       Impact factor: 3.484

Review 4.  Maternal Inflammation During Pregnancy and Offspring Brain Development: The Role of Mitochondria.

Authors:  Lauren E Gyllenhammer; Jerod M Rasmussen; Nina Bertele; Amy Halbing; Sonja Entringer; Pathik D Wadhwa; Claudia Buss
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2021-11-17

Review 5.  The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies.

Authors:  Stefania Schiavone; Luigia Trabace
Journal:  CNS Neurosci Ther       Date:  2018-03-14       Impact factor: 5.243

6.  Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways.

Authors:  Karina S MacDowell; Eva Munarriz-Cuezva; J Javier Meana; Juan C Leza; Jorge E Ortega
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

7.  Pathological Consequences of Drug Abuse: Implication of Redox Imbalance.

Authors:  Stefania Schiavone; Margherita Neri; Brian H Harvey
Journal:  Oxid Med Cell Longev       Date:  2019-09-22       Impact factor: 6.543

Review 8.  Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia.

Authors:  Giuseppe Caruso; Margherita Grasso; Annamaria Fidilio; Fabio Tascedda; Filippo Drago; Filippo Caraci
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-12

9.  Chronic N-acetylcysteine treatment improves anhedonia and cognition in a mouse model of the schizophrenia prodrome.

Authors:  Lukas Marius Bühner; Sampath K T Kapanaiah; Dennis Kätzel
Journal:  Front Behav Neurosci       Date:  2022-09-26       Impact factor: 3.617

10.  Studies on Haloperidol and Adjunctive α-Mangostin or Raw Garcinia mangostana Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats.

Authors:  Jana Lotter; Marisa Möller; Olivia Dean; Michael Berk; Brian H Harvey
Journal:  Front Psychiatry       Date:  2020-03-31       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.